Evaluation of the interaction of PNPLA3 with other genetic variants influencing steatosis and NASH, including GCKR [75], ENPP1 and IRS-1 [9], SOD2 [274], KLF6 [275], LPIN1 [278], and possibly other SNPs will be instrumental to achieve these goals. The gene discussed is LPIN1; the disease is metabolic dysfunction-associated steatohepatitis.